Skip to main content

Table 1 Clinical characteristics and assessments at baseline, post-treatment, and at 3- and 6-month follow-up (n = 25)

From: Acceptability and feasibility of enhanced cognitive behavioral therapy (eCBT) for children and adolescents with obsessive–compulsive disorder

Age (years) Gender Comorbidities (K-SADS) Medication (dose/day) Number of sessions: face-to-face/webcam CY-BOCS total score CGI–Severity /
CGI-Improvement
Pre Post 3 m 6 m Pre Post 3 m 6 m
12 M SAD, GAD, ADHD, Tic disorder, ASD Guanfacine (4 mg) 14/1 34 17 0 0 6 3/2 1/1 1/1
17 F None None 9/6 25 6 0 0 5 1/1 1/1 1/1
9 M Depression, Eating disorder None 7/1 18 11 11 21 4 1/2 1/3 5/3
16 F None None 10/11 18 14 18 N.A 4 4/3 5/3 N.A
10 F SAD, Spec. phobia, ADHD, Tic disorder None 6/1 25 0 0 0 5 1/1 1/1 1/1
10 F GAD None 6/3 24 0 0 0 4 1/1 1/1 1/1
17 M Tic disorder None 10/2 35 22 20 18 6 4/3 2/4 1/4
15 F None None 10/2 24 2 2 2 5 1/1 1/1 1/1
13 M Tic disorder None 10/6 31 8 0 0 5 4/1 1/1 1/1
12 F Eating disorder Risperidone (1 mg) 14/1 34 33 N.A 5 6 6/3 N.A 1/1
13 F GAD None 10/7 31 23 N.A N.A 6 5/3 N.A N.A
13 F None Methylphenidate (40 mg) 9/4 20 5 2 1 4 1/1 1/1 1/6
14 F None None 12/9 27 7 4 19 5 1/1 2/1 4/3
17 M ASD None 3/2 21 0 N.A N.A 5 1/1 N.A N.A
8 F None None 7/5 25 0 0 0 4 1/1 1/1 1/1
13 M None None 10/6 30 0 0 0 4 1/1 1/1 1/1
16 M N.A None 7/7 25 20 N.A N.A 5 4/3 N.A N.A
13 F ASD None 10/3 29 12 1 0 6 3/1 1/2 1/1
13 F None None 9/4 18 12 12 12 4 3/3 3/3 2/3
8 M None None 8/3 31 0 0 0 5 1/1 1/1 1/1
14 M Bipolar disorder Aripiprazole (20 mg) 4/6 21 17 N.A N.A 4 3/3 N.A N.A
17 F None None 8/9 32 0 0 0 5 1/1 1/1 1/1
8 M PTSD None 7/5 20 10 2 0 4 1/2 1/1 1/1
16 F Spec. phobia, ADHD Methylphenidate (20 mg) 11/4 21 14 6 3 5 2/1 2/1 1/1
14 M ASD, Tic disorder None 9/4 25 0 0 0 3 1/1 1/1 1/1
  1. K-SADS Kiddie Schedule for Affective Disorders and Schizophrenia, CGI Clinical Global Impression scale, CY-BOCS Children’s Yale-Brown Obsessive–Compulsive Scale, GAD Generalized Anxiety Disorder, SAD Separation Anxiety Disorder, ADHD Attention Deficit Hyperactivity Disorder, ASD Autism Spectrum Disorder, PTSD Post Traumatic Disorder, N.A. Not available, M male, F female